Figure 2
From: Identification of Polo-like kinases as potential novel drug targets for influenza A virus
PLK inhibitors efficiently block IAV replication at non-toxic concentrations. The PLK inhibitors BI2536, Rigosertib, GW843682X and NMS-1286937 were used at different concentrations to investigate their effect on replication of recombinant influenza A WSN-Renilla luciferase virus (WSN-Ren). (A) PLK inhibitors block IAV in MDCK cells. MDCK-HA cells were pretreated with PLK inhibitors at the indicated concentrations for 2 h and subsequently infected with WSN-Ren at MOI 0.1 or mock treated for 30 hours in presence of inhibitors. Viral replication was assessed by luciferase activity relative to DMSO as control. Cell viability was determined using quantitation of ATP by luminescence relative to DMSO as control. Data were combined from three individual experiments with at least two replicates each. Shown are means with standard deviation. (B) PLK inhibitors block IAV in A549 cells. A549 cells were pretreated with PLK inhibitors at the indicated concentrations for 2 h, infected with WSN-Ren at MOI 3 or mock treated for 6 hours in the presence of inhibitors. Viral replication was assessed by measuring luciferase activity relative to DMSO as control. Data were combined from four experiments with two or more replicates each; shown are means with standard deviation.
